Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy VistaGen Therapeutics stock | 0.72

Own VistaGen Therapeutics stock in just a few minutes.

Posted

Fact checked

VistaGen Therapeutics, Inc is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 9 staff and has a trailing 12-month revenue of around USD$334,000.

How to buy shares in VistaGen Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for VistaGen Therapeutics. Find the stock by name or ticker symbol: VTGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until VistaGen Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$0.72, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of VistaGen Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of VistaGen Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted VistaGen Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, VistaGen Therapeutics's share price has had significant positive movement.

Its last market close was USD$0.72, which is 3.22% up on its pre-crash value of USD$0.6968 and 140.00% up on the lowest point reached during the March crash when the shares fell as low as USD$0.3.

If you had bought USD$1,000 worth of VistaGen Therapeutics shares at the start of February 2020, those shares would have been worth USD$461.50 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$946.12.

VistaGen Therapeutics share price

Use our graph to track the performance of VTGN stocks over time.

VistaGen Therapeutics shares at a glance

Information last updated 2020-11-26.
Latest market close USD$0.72
52-week range USD$0.3 - USD$1.06
50-day moving average USD$0.7319
200-day moving average USD$0.6485
Wall St. target price USD$4.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.829

Buy VistaGen Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy VistaGen Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

VistaGen Therapeutics price performance over time

Historical closes compared with the close of $0.72 from 2020-11-16

1 week (2020-11-20) N/A
1 month (2020-10-30) 0.72
3 months (2020-08-28) N/A
6 months (2020-05-28) N/A
1 year (2019-11-27) N/A
2 years (2018-11-27) N/A
3 years (2017-11-27) N/A
5 years (2015-11-27) N/A

VistaGen Therapeutics financials

Revenue TTM USD$334,000
Gross profit TTM USD$0
Return on assets TTM -67.41%
Return on equity TTM -293.91%
Profit margin 0%
Book value $0.057
Market capitalisation USD$59 million

TTM: trailing 12 months

Shorting VistaGen Therapeutics shares

There are currently 2.9 million VistaGen Therapeutics shares held short by investors – that's known as VistaGen Therapeutics's "short interest". This figure is 9.2% down from 3.2 million last month.

There are a few different ways that this level of interest in shorting VistaGen Therapeutics shares can be evaluated.

VistaGen Therapeutics's "short interest ratio" (SIR)

VistaGen Therapeutics's "short interest ratio" (SIR) is the quantity of VistaGen Therapeutics shares currently shorted divided by the average quantity of VistaGen Therapeutics shares traded daily (recently around 695968.34532374). VistaGen Therapeutics's SIR currently stands at 4.17. In other words for every 100,000 VistaGen Therapeutics shares traded daily on the market, roughly 4170 shares are currently held short.

However VistaGen Therapeutics's short interest can also be evaluated against the total number of VistaGen Therapeutics shares, or, against the total number of tradable VistaGen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VistaGen Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 VistaGen Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0428% of the tradable shares (for every 100,000 tradable VistaGen Therapeutics shares, roughly 43 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VistaGen Therapeutics.

Find out more about how you can short VistaGen Therapeutics stock.

VistaGen Therapeutics share dividends

We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months.

Have VistaGen Therapeutics's shares ever split?

VistaGen Therapeutics's shares were split on a 1:20 basis on 14 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.

VistaGen Therapeutics share price volatility

Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.3 up to $1.06. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.4515. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).

VistaGen Therapeutics overview

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines to treat diseases and disorders of the central nervous system. It focuses on depressive and social anxiety disorders. The company's lead product candidate is AV-101 that is in Phase II clinical trial for the treatment of chronic neuropathic pain, epilepsy, major depressive disorder (MDD), parkinson's disease levodopa-induced dyskinesia, and suicidal ideation; PH94B, a neuroactive nasal spray that is in Phase III clinical trial for social anxiety disorder (SAD), and Phase IIa clinical trial for generalized anxiety disorder; and PH10, a neuroactive nasal spray that is in Phase IIb clinical trial for MDD. It has licensing, sublicensing, and collaboration agreements with Pherin Pharmaceuticals, Inc.; BlueRock Therapeutics, LP; and Cato Research Ltd. The company also has a strategic licensing and collaboration agreement with EverInsight Therapeutics Inc. for the clinical development and commercialization of PH94B for multiple anxiety-related disorders in Greater China, South Korea, and Southeast Asia. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site